Catalent today announced that two of its experts have been invited to speak at the upcoming Waterside Conference.

Catalent today announced that one of its scientific experts will host a workshop during KNect365 Life Sciences’ annual Well Characterized Biologics & Biological Assays conference.

Catalent today announced that Christopher Hepler, Group Leader, Biologics Analytical Services, Catalent Biologics has been invited to speak at the upcoming 16th Annual Congress of International Drug Discovery Science & Technology.

Catalent Pharma Solutions and Berkeley Lights, Inc., a leader in digital cell biology, today announced Catalent Biologics will adopt BLI’s Beacon® optofluidic platform to accelerate its cell line development workflow.

Catalent Pharma Solutions today announced that Graham Brearley, Ph.D., has been appointed as General Manager of the company’s Madison, Wisconsin facility.

Catalent today welcomed the news that InterveXion has enrolled the first patient in STAMPOUT, the first trial in methamphetamine users of the first-in-class anti-methamphetamine antibody IXT-m200.

Catalent and Valerius Biopharma AG, a Swiss biopharmaceutical company, today announced that they are to collaborate on the development and manufacture of Valerius’ biosimilar products.

Catalent today announced that several of its formulation and manufacturing experts are to present and participate in the educational agenda at the INTERPHEX Conference and Exhibition, to be held the Javits Center.

Catalent today announced it has won ten categories in the annual CMO Leadership Awards. The Awards recognize top outsourcing partners, determined by feedback from sponsor companies who outsource manufacturing.